ABT-737 is a small molecule Bcl-2 homology (BH)-3 domain mimetic that binds to the Bcl-2 family proteins Bcl-2 and Bcl-xL and is currently under investigation in the clinic. In this study, we investigated potential mechanisms of resistance to ABT-737 in leukemia cell lines. 
Introduction
The interplay between Bcl-2 family members is essential for controlling the mitochondrial cell death pathway and thereby the survival of most cells, including those of hematopoietic origin.
Based on their Bcl-2 homology (BH) domains, the Bcl-2 proteins have been grouped in three classes: anti-apoptotic (containing the BH1-BH4 domains), pro-apoptotic, containing the BH1-BH3 domains, and those with the BH3 domain-only (1, 2) . The members of this group regulate mitochondrial outer membrane permeabilization (MOMP), monitoring release of cytochrome c and activating downstream effector caspases (3) . The imbalance in expression of these partners has been implicated in development of various tumor types and resistance to chemotherapeutic regimens (1) . This often results from high-level expression of anti-apoptotic members, such as Bcl-2, Bcl-xL, Mcl-1, Bcl-w, and Bfl-1 that prevent cell death by sequestering BH3-only proteins, such as Bim, Puma, and Noxa, and regulate activation of the pro-apoptotic proteins Bax and Bak. In most of these cases, up-regulation and binding of significant amounts of anti-apoptotic proteins to activator proteins keeps these cells alive (1, 2, 4, 5) .
ABT-737 is a small molecule inhibitor that is effective against certain Bcl-2 family members. It has a strong affinity for Bcl-2, Bcl-xL, and Bcl-w that are bound to Bim (6) by releasing Bim from anti-apoptotic Bcl-2 partners, thereby initiating MOMP. The oral derivative of ABT-737, navitoclax (ABT-263) is currently under investigation in several clinical trials in lymphoid malignancies, such as chronic lymphocytic leukemia (CLL), and tumors, such as small cell lung cancer (7) (8) (9) (10) . Importantly, ABT-737-mediated cell death is Bax/Bak-dependent as Nalm-6 and Reh cells were cultured in increasing concentrations of ABT-737 administered intermittently, with the drug being washed off to allow cells to recover. Gradually, the ABT-737 concentration was increased until cells remained viable when concentrations double to that of their IC50 value was administered continuously. Cells were treated with verapamil (Sigma-Aldrich) to exclude the possibility of acquiring resistance due to increase in expression of drug efflux pumps (7, 17) . The ABT-R cells were routinely monitored for resistance to ABT-737; they were cultured without drug for 72 h before performing experiments.
Flow cytometry
Cell death was measured by phosphatidylserine externalization 
Immunoblotting and immunoprecipitation
Protein lysates were prepared with 1% NP-40 lysis buffer (20 mM Tris-HCl, pH 7.5; 150 mM Nacl; 1 mM EDTA; 1% NP-40) containing protease inhibitors (Roche) and phosphatase inhibitors cocktail 2 and 3 (Sigma). The cells were lysed for 30-45 min at 4 0 C. 50-60 g of protein was resolved on 10%-12% SDS-PAGE, transferred to nitrocellulose membrane, and immunoblotting was performed with primary antibodies. For immunoprecipitation cells were lysed with CHAPS buffer (20 mM Tris-HCl, pH 7.5; 150 mM NaCl; 1 mM EDTA; 2% CHAPS, Calbiochem) containing protease and phosphates inhibitors for 1 h. Protein lysates were incubated with primary antibody overnight at 
RNA Isolation and Real-Time Quantitative Polymerase Chain Reaction (qRT-PCR)
RNA isolated from parental and ABT-R cells after ABT-737 treatment (500-1000 nM) for 4-24 h was examined by qRT-PCR, using primers for Mcl-1 and NOXA, and normalized for -actin as described (5) . Similar experiments were performed with ABT-R cells followed by gossypol (10 μM) at 12 h. The half-life of Mcl-1 mRNA was determined following actinomycin D treatment and qRT-PCR analysis.
Genetic manipulation of Mcl-1 and NOXA
NOXA knockdown was achieved in ABT-R Nalm-6 and Reh cells by shRNA delivered by lentivirus transduction (5) . Single cell clones with stable expression of shNOXA (Santa Cruz; sc-37305-V), shMcl-1 (Sigma-Aldrich: NM_021960.3-3125s1c1, NM_021960.3-1001s1c1) and scrambled shRNA (control; sc-108080) were selected with puromycin (Sigma-Aldrich). NOXA shRNA lentiviral particles were obtained as a pool of concentrated, transduction-ready viral particles containing three target-specific constructs that encode 19-25 nt (plus hairpin). Mcl-1 shRNA lentiviral particles were prepared according to manufacturer's protocol.
Research. 
Statistical Analysis
Statistical comparisons between groups were conducted by 2-way ANOVA using Prism software. Standard deviation was calculated from experiments performed in triplicates and indicated as error bars. All experiments were repeated three times independently.
Results

Acquired resistance of B-cells to ABT-737 after prolonged exposure
ABT-737 is a BH3-mimetic that binds only to certain Bcl-2 family proteins, such as Bcl-2, Bcl-xL, and Bcl-w, but not Mcl-1. In our previous studies we have shown that patients with increased Mcl-1 levels do not respond to ABT-737 and thereby become resistant to this drug (5) . Hence, in order to investigate the mechanism responsible for resistance, we generated ABT-737-resistant (ABT-R) cell lines from initially sensitive pre-B Nalm-6 and Reh cells. These cell lines were selected for their sensitivity to ABT-737, with IC50 values of ~1000 and ~500 nm, respectively. The Nalm-6 ABT-R and Reh ABT-R cells generated could tolerate continuous exposure to ABT-737 at a concentration double to that of their IC50 value (Fig. 1A) . It has been known that ABT-737 triggers Bax/Bak-mediated apoptosis (11) . ABT-737 treatment led to Bax activation, as indicated by 6A7 antibody reactivity in Nalm-6 and Reh cells, but not in their resistant derivatives (Fig. 1B) . These results are in support of how resistant cells could evade Bax-mediated apoptosis caused by ABT-737. Further examination of Bcl-2 family proteins by immunoblotting in parental and ABT-R cells indicated increased Mcl-1 levels in ABT-R cells (Fig. 1C) . Bfl-1 levels were below our detection limit. We could also observe decreased Bcl-2 and increased Bim levels in Reh ABT-R cells, which were comparable to those found in Nalm-6 ABT-R cells. Puma and NOXA expression was not markedly altered (Fig. 1C) . Mcl-1 protein levels increased in parental but not in ABT-R cells following acute ABT-737 treatment (Fig. 1D ). Supplementary Fig. S1C ). Parental cells were sensitive to ABT-737 and within 3 h they were committed to cell death, as indicated by cleavage of poly-(ADP-ribose) polymerase 1 (PARP1). Increased Mcl-1 levels were attributed to increased deubiquitination as a result of increased levels of the USP9X deubiquitinating enzyme (19) , however, USP9X levels ( We next explored the mechanism responsible for the differences in the ability of Mcl-1 to bind Bim in ABT-R compared to parental cells. It has been shown that Mcl-1 Ser-64 phosphorylation is associated with enhanced binding to proapoptotic proteins, such as Bim, NOXA, and Bak (18) . Interestingly, Mcl-1 was phosphorylated on Ser-64 in ABT-R Reh and Nalm-6, but not in parental cells (Fig. 3C) . In contrast, while Mcl-1 levels increased, nevertheless Mcl-1 Ser-64 phosphorylation was not detected in Nalm-6 following 1-2 h acute treatment with ABT-737 ( Fig. 3C ; LHS). These findings suggest that Mcl-1, the levels of which increased following ABT-737 treatment in parental cells, failed to associate with Bim due to lack (20) . Indeed, Mcl-1 was phosphorylated on Thr163 in ABT-R Nalm-6 and Reh, but not in parental cells ( Fig. 3D; LHS) . Erk was also activated, as indicated by p-Erk expression in ABT-R but not the parental cells ( Fig. 3D; RHS) . These results indicate that phosphorylation of Mcl-1 at specific residues has developed during acquired resistance to ABT-737 treatment. These Mcl-1 postranslational modifications facilitate its interaction with Bim, leading to increased Mcl-1 protein stability in ABT-R cells, as previously suggested (21, 22) .
Gossypol sensitizes ABT-737-resistant cells by up-regulating NOXA
To overcome Mcl-1-dependent acquired resistance, parental and resistant cells were treated with increasing concentrations of gossypol. Annexin V FITC-PI staining ( Supplementary   Fig. S2A ), and trypan blue exclusion (Fig. 4A) , indicated that ABT-R cells were exquisitely sensitive to gossypol treatment compared to parental cells. In addition, Cyclin E cleavage, another marker of apoptosis (23, 24) was generated in ABT-R cells (data not shown). Timecourse experiments with gossypol showed maximum cell death at 24 h. To study the mechanism of its action and avoid consequences of cell death, the 18 h time-point and a 10 μM gossypol dose were chosen, as the minimum concentration at which ABT-R but not parental cells were most sensitive (all other experiments used gossypol at 10 μM for 18 h, unless otherwise stated). Mcl-1 protein stability was not altered substantially following gossypol treatment in ABT-R cells (data not shown). The levels of anti-apoptotic and pro-apoptotic proteins were next examined in ABT-R Nalm-6 (LHS) and Reh cells (RHS) following a 6-18 h exposure to gossypol (Fig. 4B) . Interestingly, a low molecular weight Mcl-1 species was present, most likely an alternative splice variant of Mcl-1 (Mcl-1s), which has been reported to function as a pro-apoptotic molecule (25) . The expression of NOXA increased greatly in a time-dependent manner (Fig. 4B) . Bcl-xL and Bcl-2 levels were downregulated following treatment in Reh ABT- Fig. 4B; RHS) , however PUMA levels did not change significantly (data not shown).
R cells (
There was a modest increase in Mcl-1 levels in Nalm-6 cells following gossypol treatment, and those of NOXA also increased less compared to ABT-R cells (Supplementary Fig. S2B ). When NOXA and Mcl-1 mRNA levels were examined at 12 h following gossypol treatment there was a 5-6-fold increase of Mcl-1 mRNA and a robust 20 to 25-fold induction of NOXA levels in ABT-R cells (Fig. 4C) . These findings indicate that up-regulation of Mcl-1 and NOXA following gossypol treatment was at mRNA level.
It has been reported that obatoclax (GX15-070), similarly to gossypol, targets Mcl-1 (26) and is predicted to overcome Mcl-1-dependent ABT-737 resistance (27) . Indeed, Nalm-6 ABT-R cells were sensitive to obatoclax, however Nalm-6 cells were equally sensitive (IC50: 10 µM).
Reh parental cells (IC50: 5 µM) were also more sensitive to obatoclax compared to ABT-R cells as measured by trypan blue exclusion (Supplementary Fig. S3A ). Mcl-1 protein levels were downregulated following obataclax treatment. Noxa levels also increased, however these changes did not correlate with cell death (Supplementary Fig. S3B ). Hence, gossypol was used for further studies, as it selectively sensitizes ABT-R cells.
NOXA expression mediates gossypol-induced cell death
To determine whether NOXA induction and cell death are a consequence of caspase activation, ABT-R Nalm-6 and Reh cells were treated with a pan-caspase inhibitor prior to gossypol treatment. zVAD-fmk addition prevented caspase activation, but not NOXA induction and generation of Mcl-1(s) (Fig. 5A ). To directly demonstrate a critical role for NOXA for the gossypol response, NOXA was depleted by shRNA in ABT-R Nalm-6 and Reh cells, under conditions in which Mcl-1 and Bim levels were unaltered. Remarkably, NOXA knockdown ( Fig.   5C ) prevented significantly gossypol-induced cell death of ABT-R Nalm-6 (p=0.003) and Reh cells (p=0.008) (Fig. 5B) independent clones) restored resistance to gossypol treatment as measured by trypan blue exclusion (Nalm-6 ABT-R, p=0.001; Reh ABT-R, p=0.007) (Fig. S2D ) and PARP1 cleavage (data not shown). These data demonstrate that gossypol is more effective in Mcl-1-dependent ABT-R cells.
Association of NOXA with Mcl-1 leads to release of Bim following gossypol treatment
Next, to address the mechanism of sensitization by gossypol, the Mcl-1/Bim association was examined. Bim immunoprecipitation revealed that Mcl-1 was no longer associated with Bim in Nalm-6 ABT-R cells following gossypol treatment, indicating that the Bim/Mcl-1 complex was disrupted ( Fig. 6A; LHS) . In contrast, Bcl-2 and Bcl-xL were still bound to Bim in these Nalm-6
and Reh ABT-R cells (Supplementary Fig. S2C ). Moreover, Mcl-1 pull-down revealed that NOXA interaction with Mcl-1 facilitated Bim release from the Mcl-1/Bim complex in ABT-R cells (Fig. 6B) . The released Bim, present in the supernatant (Supplementary Fig. S2E ), most likely initiated gossypol-induced mitochondrial cell death. The Bim/Mcl-1 complex was also disrupted by NOXA in parental cells but to a lesser extent and with a slower kinetics compared to ABT-R cells (Fig. 6A) . To determine the direct effect of Noxa on the Mcl-1/Bim association after gossypol treatment, NOXA levels were downregulated by shRNA. Interestingly, shRNAmediated NOXA knockdown not only prevented cell death but also the release of Bim from Mcl-1 and Mcl-1(s) genesis in ABT-R Nalm-6 and Reh cells following gossypol treatment (Fig. 5B,   6C ). These results indicate that the association of NOXA with Mcl-1 in ABT-R cells following gossypol treatment lead to release of Bim that was critical for inducing mitochondrial cell death. Gossypol has a significant antitumor activity against lymphoma, head and neck, and prostate cancer through induction of Noxa and Puma (35) (36) (37) . Obatoclax is a small molecule that disrupts interaction between Mcl-1 and Bak and hence shows potential to overcome ABT-737 resistance (27) . While obatoclax was effective against ABT-R cells, it did not have specificity for ABT-737-resistant cells. In contrast, gossypol emerges from this study as a very potent compound Mcl-1, thereby displacing Bim, leading to cell death ( Fig. 6D and E) . Gossypol, a natural product has been shown to be effective in inducing apoptosis as well as autophagy-mediated cell death in various cancer cell lines and xenograft tumor models as pan-Bcl-2 inhibitor (35, 36, 46) . It is possible that apogosspyol, its semisynthetic derivative with structural modifications that increase its affinity for anti-apoptotic Bcl-2 proteins and reduces its toxic effects could be also effective in ABT-737-resistant patients, as both are under evaluation in phase I/II clinical trials for CLL and several other malignancies, such as prostate, lung, and brain tumors. These findings provide insights into the molecular mechanism of ABT-737 resistance and how it can be overcome with gossypol, which can be considered for clinical treatment of navitoclax-resistant leukemia patients. 
